Grupp: Huvudforum
NasdaqCM: ASTM
Ännu en potentiell dubblare/tripplare 2011!
Aastrom Biosciences, Inc.'s Corporate Governance Quotient (CGQ®) as of Oct 1, 2010 is better than 73.7% of CGQ Universe companies and 50.7% of Pharmaceuticals, Biotechnology & Life Sciences companies.
Charts
Business Summary
Aastrom Biosciences, Inc., a regenerative medicine company, engages in developing autologous cell therapies for the treatment of severe and chronic cardiovascular diseases. The company’s autologous expanded cellular therapy technology uses single-pass perfusion to produce human cell products for clinical use. Its clinical development programs include CLI program, which is in phase IIb clinical development for the treatment of serious and advanced stage of peripheral arterial diseases; and DCM development program, which is in Phase II for the treatment of dilated cardiomyopathy (DCM). The company also has two ongoing U.S. Phase II trials investigating surgical and catheter-based delivery for its product in the treatment of DCM. Aastrom Biosciences, Inc. was founded in 1989 and is headquartered in Ann Arbor, Michigan.
Mvh /B